- Home
- OCUL vs ARQT Comparison
OCUL vs ARQT Comparison
Compare OCUL & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCUL
- ARQT
- Stock Information
- Founded
- OCUL 2006
- ARQT 2016
- Country
- OCUL United States
- ARQT United States
- Employees
- OCUL N/A
- ARQT N/A
- Industry
- OCUL Biotechnology: Pharmaceutical Preparations
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- OCUL Health Care
- ARQT Health Care
- Exchange
- OCUL Nasdaq
- ARQT Nasdaq
- Market Cap
- OCUL 1.4B
- ARQT 1.1B
- IPO Year
- OCUL 2014
- ARQT 2020
- Fundamental
- Price
- OCUL $8.01
- ARQT $12.68
- Analyst Decision
- OCUL Strong Buy
- ARQT Strong Buy
- Analyst Count
- OCUL 8
- ARQT 5
- Target Price
- OCUL $16.50
- ARQT $17.00
- AVG Volume (30 Days)
- OCUL 874.8K
- ARQT 2.1M
- Earning Date
- OCUL 03-10-2025
- ARQT 02-25-2025
- Dividend Yield
- OCUL N/A
- ARQT N/A
- EPS Growth
- OCUL N/A
- ARQT N/A
- EPS
- OCUL N/A
- ARQT N/A
- Revenue
- OCUL $61,442,000.00
- ARQT $138,708,000.00
- Revenue This Year
- OCUL $11.40
- ARQT $209.03
- Revenue Next Year
- OCUL $13.58
- ARQT $49.00
- P/E Ratio
- OCUL N/A
- ARQT N/A
- Revenue Growth
- OCUL 6.45
- ARQT 182.84
- 52 Week Low
- OCUL $3.76
- ARQT $3.11
- 52 Week High
- OCUL $11.78
- ARQT $16.20
- Technical
- Relative Strength Index (RSI)
- OCUL 38.27
- ARQT 43.06
- Support Level
- OCUL $7.99
- ARQT $13.10
- Resistance Level
- OCUL $8.43
- ARQT $14.36
- Average True Range (ATR)
- OCUL 0.38
- ARQT 0.99
- MACD
- OCUL -0.03
- ARQT -0.32
- Stochastic Oscillator
- OCUL 20.66
- ARQT 1.95
About OCUL Ocular Therapeutix Inc.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.